Skip to main content

Table 1 Key model parameters

From: Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort

Parameters Estimates Distribution
Patient generation state
 Age (years) Empirical Beta Mean (sd): 67.8 (14.7)
Beta (3.73, 2.32)
Sex
 Age ≤40 Male: 0.56 Beta α = 9, β = 7
 Age 40–50 Male: 0.68 Beta α = 15, β = 7
 Age 50–60 Male: 0.71 Beta α = 29, β = 12
 Age 60–70 Male: 0.50 Beta α = 31, β = 31
 Age 70–80 Male: 0.55 Beta α = 42, β = 35
 Age ≥80 Male: 0.51 Beta α = 27, β = 26
Diagnosis
Diagnostic test results
 Age ≤40 Stage IA: 0.06 Dirichlet α 1 = 2
CNS involvement: 0.0   α 2 = 1
Standard: 0.94 α 3 = 16
Died before diagnosis: 0.0 α 4 = 2
 Age 40–50 Stage IA: 0.09 Dirichlet α 1 = 3
CNS involvement: 0.09   α 2 = 3
Standard: 0.77 α 3 = 18
Died before diagnosis: 0.05 α 4 = 2
 Age 50–60 Stage IA: 0.15 Dirichlet α 1 = 7
CNS involvement: 0.08   α 2 = 4
Standard: 0.75 α 3 = 32
Died before diagnosis: 0.02 α 4 = 2
 Age 60–70 Stage IA: 0.06 Dirichlet α 1 = 5
CNS involvement: 0.02   α 2 = 2
Standard: 0.90 α 3 = 57
Died before diagnosis: 0.02 α 4 = 2
 Age 70–80 Stage IA: 0.12 Dirichlet α 1 = 10
CNS involvement: 0.01   α 2 = 2
Standard: 0.75 α 3 = 59
Died before diagnosis: 0.12 α 4 = 10
 Age ≥80 Stage IA: 0.05 α 1 = 4
CNS involvement: 0.00 α 2 = 1
Standard: 0.89 α 3 = 48
Died before diagnosis: 0.06 α 4 = 4
Initial treatment decision
 Age ≤40 Treated: 0.94 Beta α = 15, β = 1
 Age 40–50 Treated: 0.95 Beta α = 21, β = 1
 Age 50–60 Treated: 0.96 Beta α = 39, β = 2
 Age 60–70 Treated: 0.88 Beta α = 55, β = 7
 Age 70–80 Treated: 0.75 Beta α = 58, β = 19
 Age ≥80 Treated: 0.54 Beta α = 29, β = 24
Treatment decision for patients refractory to first-line chemotherapy
 Age ≤60 Treated: 0.86 Beta α = 6, β = 1
 Age 60–80 Treated: 0.33 Beta α = 4, β = 8
 Age ≥80 Treated: 0.00 Beta α = 0, β = 6
Treatment decision for patients relapsed following first-line chemotherapy
 Age ≤60 Treated: 0.93 Beta α = 14, β = 1
 Age 60–80 Treated: 0.53 Beta α = 8, β = 7
 Age ≥80 Treated: 1.00 Beta α = 2, β = 0
Treatment decision for patients refractory to second-line chemotherapy
 Age ≤60 Treated: 0.50 Beta α = 4, β = 4
 Age 60–80 Treated: 0.50 Beta α = 3, β = 3
 Age ≥80 Treated: 0.00 Beta α = 0, β = 1
Treatment decision for patients relapsed following second-line chemotherapy
 Age ≤60 Treated: 0.50 Beta α = 1, β = 1
 Age 60–80 Treated: 0.00 Beta α = 0, β = 1
 Age ≥80 Treated: 0.00 Beta α = 0, β = 1
Treatment decision for patients refractory to third-line chemotherapy
 Age ≤60 Treated: 0.50 Beta α = 0, β = 3
 Age 60–80 Treated: 0.00 Beta α = 0, β = 1
 Age ≥80 Treated: 0.00a Beta α = 0, β = 1
Treatment decision for patients relapsed following third-line chemotherapy
 Age ≤60 Treated: 0.50a Beta α = 1, β = 1
 Age 60–80 Treated: 0.00a Beta α = 0, β = 1
 Age ≥80 Treated: 0.00a Beta α = 0, β = 1
  1. CNS central nervous system
  2. aThe probability was assumed to be the same as the probability in the second line due to lack of data